HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Romppanen, E.-L. Articles by Mononen, I. Search for Related Content PubMed PubMed Citation Articles by Romppanen, E.-L. Articles by Mononen, I. Related Collections Molecular Diagnostics and Genetics

Detection of the Finnish-Type Congenital Nephrotic Syndrome by Restriction Fragment Length Polymorphism and Dual-Color Oligonucleotide Ligation Assays

¹ Kuopio University Hospital, Department of Clinical Chemistry, FIN-70211 Kuopio, Finland.

² Kuopio University, Department of Clinical Chemistry, FIN-70211 Kuopio, Finland.

³ Turku University Central Hospital, Department of Clinical Chemistry and Hematology, FIN-20521 Turku, Finland.
^a Address correspondence to this author at: Turku University Central Hospital, Department of Clinical Chemistry and Hematology, PO Box 52, FIN-20521 Turku, Finland. Fax 358-2-2613924; e-mail ilkka.mononen{at}tyks.fi

Background: Congenital nephrotic syndrome of Finnish type (NPHS1) is an autosomal recessive disorder characterized by severe proteinuria of intrauterine onset. Ninety-four percent of the Finnish NPHS1 chromosomes have been reported to carry either a 2-bp deletion in exon 2 (Fin_Major) or a nonsense mutation in exon 26 (Fin_Minor) of the NPHS1 gene. The high prevalence of only two mutations in the Finnish population enables the use of molecular techniques in the diagnosis of NPHS1 and for carrier screening.

Methods and Results: We describe two different molecular methods for the detection of the NPHS1 mutations: a PCR-restriction fragment length polymorphism (PCR-RFLP) and a dual-color oligonucleotide ligation assay (OLA). The dual-color OLA, which enables simultaneous detection of the NPHS1 Fin_Major and Fin_Minor mutations, can be used for rapid analysis of large sets of samples. The analysis of 2004 Finnish blood samples revealed 34 carriers of the Fin_Major mutation and 1 carrier of the Fin_Minor mutation, indicating a carrier frequency of 1:59 (95% confidence interval, 1:89–1:44) for the NPHS1 Fin_Major mutation and 1:2004 (95% confidence interval, 0 to 1:677) for the NPHS1 Fin_Minor mutation, respectively.

Conclusion: PCR-RFLP and dual-color OLA are suitable for molecular diagnosis and carrier screening of the major mutations that cause NPHS1.

The following articles in journals at HighWire Press have cited this article:

				A. Kitamura, H. Tsukaguchi, K. Iijima, J. Araki, M. Hattori, M. Ikeda, M. Honda, K. Nozu, H. Nakazato, N. Yoshikawa, et al. Genetics and clinical features of 15 Asian families with steroid-resistant nephrotic syndrome Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3133 - 3138. [Full Text] [PDF]

				T. Pastinen, M. Perola, J. Ignatius, C. Sabatti, P. Tainola, M. Levander, A.-C. Syvanen, and L. Peltonen Dissecting a population genome for targeted screening of disease mutations Hum. Mol. Genet., December 1, 2001; 10(26): 2961 - 2972. [Abstract] [Full Text] [PDF]